BORTELIEVA 3.5MG ( Bortezomib Injection IP 3.5mg )

BORTLIEVA contains Bortezomib, a proteasome inhibitor used in cancer treatment. It works by blocking proteasomes in cells, leading to accumulation of proteins and apoptosis (cell death) of cancer cells.

Bortezomib is used in adults for:

1. Multiple myeloma
     – Newly diagnosed or relapsed/refractory

2. Mantle cell lymphoma
     – Previously treated patients

3. Sometimes in combination with other chemotherapies for certain hematologic cancers.

Common side effects:

•  Fatigue, weakness

•  Peripheral neuropathy (tingling/numbness)

•  Nausea, vomiting

•  Diarrhea or constipation

•  Low blood counts (thrombocytopenia, neutropenia)

Serious side effects:

•  Severe infections

•  Severe neuropathy

•  Heart problems (rare)

•  Liver function abnormalities

Monitor blood counts and liver function regularly.

•  1.3 mg/m² IV or SC on Days 1, 4, 8, 11 of a 21-day cycle (common regimen)

•  Dose may be adjusted based on side effects or prior therapies

•  Can be given intravenously (IV) or subcutaneously (SC)

NOTE: This medicine should be taken only under a doctor’s supervision.